3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 1/2
2
Phase 4
1
Status
Unknown
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Conditions
Recurrence
1
Multiple Myeloma
1
Leukemia, Myeloid, Chronic-Phase
1
Interventions
Cyclophosphamide
37
Gemcitabine
31
Paclitaxel
27
Cisplatin
27
Carboplatin
27
Capecitabine
27
camrelizumab
24
Nivolumab
23
apatinib
22
Oxaliplatin
21
fludarabine
20
Radiotherapy
20
toripalimab
17
Immunotherapy, Adoptive
17
Drug Therapy
17
pembrolizumab
16
Docetaxel
16
Dexamethasone
15
Bevacizumab
15
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
14
Injections
14
tislelizumab
13
Temozolomide
13
Rituximab
13
Cetuximab
13
Irinotecan
12
130-nm albumin-bound paclitaxel
11
anlotinib
10
Fluorouracil
10
Trastuzumab
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Unknown
×
Pioglitazone
×
Clear all
NCT02767063
2020-08-07
ACTIW
Versailles Hospital
Phase 1/2
Unknown
100 enrolled
NCT01010243
2012-05-30
MM03
University of Regensburg
Phase 1/2
Unknown
54 enrolled